Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) Director Edgar Engleman sold 31,257 shares of the stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $0.92, for a total transaction of $28,756.44. Following the sale, the director now owns 269,823 shares in the company, valued at approximately $248,237.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Edgar Engleman also recently made the following trade(s):
- On Thursday, November 16th, Edgar Engleman sold 8,571 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $0.96, for a total transaction of $8,228.16.
Bolt Biotherapeutics Stock Performance
NASDAQ BOLT traded down $0.03 on Monday, hitting $0.91. The stock had a trading volume of 184,152 shares, compared to its average volume of 165,264. Bolt Biotherapeutics, Inc. has a one year low of $0.86 and a one year high of $2.03. The company has a quick ratio of 7.42, a current ratio of 6.69 and a debt-to-equity ratio of 0.14. The stock has a market cap of $34.73 million, a price-to-earnings ratio of -0.48 and a beta of 0.83. The company’s 50-day moving average is $1.01 and its two-hundred day moving average is $1.28.
Analysts Set New Price Targets
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its position in Bolt Biotherapeutics by 742.1% in the 4th quarter. JPMorgan Chase & Co. now owns 19,908 shares of the company’s stock worth $26,000 after purchasing an additional 17,544 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Bolt Biotherapeutics by 130.4% in the third quarter. Tower Research Capital LLC TRC now owns 18,537 shares of the company’s stock valued at $28,000 after acquiring an additional 10,492 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Bolt Biotherapeutics in the second quarter valued at approximately $30,000. Prudential Financial Inc. bought a new position in shares of Bolt Biotherapeutics in the second quarter valued at approximately $33,000. Finally, PDT Partners LLC bought a new position in shares of Bolt Biotherapeutics in the first quarter valued at approximately $33,000. Institutional investors own 73.56% of the company’s stock.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
- Five stocks we like better than Bolt Biotherapeutics
- Find and Profitably Trade Stocks at 52-Week Lows
- The most upgraded stocks in November have two things in common
- What is Forex and How Does it Work?
- Monday.com rocked earnings like it’s the weekend
- CD Calculator: Certificate of Deposit Calculator
- Plan to own one retailer? Make it this one
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.